Well the space this company is in, seems interesting.
Growing 50% yoy.
And recently this startup raises a funding too who works in same domain:
They also operate from Pune. How do you folks see the competition?
Well the space this company is in, seems interesting.
Growing 50% yoy.
And recently this startup raises a funding too who works in same domain:
They also operate from Pune. How do you folks see the competition?
Globally renowned US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222). This is 1st time ever that an antibiotic has been granted a susceptible breakpoint of as high as 64 mg/L for all the three families of Gram negative pathogens; Enterobacterales, Pseudomonas and Acinetobacter.
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!